AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Crinetics Pharmaceuticals, Inc. Director's Dealing 2021

Feb 5, 2021

31156_dirs_2021-02-05_57d65494-cb7b-43fa-8db6-1babded4b728.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 5 — Annual Statement of Changes in Beneficial Ownership

Issuer: Crinetics Pharmaceuticals, Inc. (CRNX)
CIK: 0001658247
Period of Report: 2020-12-31

Reporting Person: Krasner Alan Seth (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-05-20	Common Stock	J	1165	$14.45	Acquired	6106	Direct
2020-11-20	Common Stock	J	277	$11.61	Acquired	6383	Direct

Footnotes

F1: Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c),